Allogene IPO could be year's largest biotech listing on NASDAQ

In newly proposed terms for its planned IPO on NASDAQ, cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) hopes to sell 16 million shares at $16-$18. At the midpoint, Allogene would raise $272 million and be valued at $1.9 billion.

Allogene had filed on Sept. 14 to raise up to $100 million in the offering; the company amended the offering on Oct. 2. Underwriters are Goldman Sachs, J.P. Morgan, Cowen and Jefferies...